Amazon CEO Andy Jassy told investors that he's "confident" the company will see a return on its massive investments in artificial intelligence. The company boosted its 2026 capital expenditures to $200 billion, with most of the spending going to data centers.
Amazon's Q4 earnings call on Thursday (Feb. 5) produced the number everyone repeated: CEO Andy Jassy said Amazon expects to invest about $200 billion in capital expenditures in 2026, “predominantly in AWS,” to add capacity for AI and core cloud workloads. But the call wasn't only an AI-capex story.
Novo Nordisk has launched its Wegovy GLP-1 drug in pill form. Amazon is getting into the fight, offering ease and low costs to customers who buy the Wegovy pill on its platform.
Amazon plans $200 billion in capex this year, far more than Wall Street expected. AWS revenue growth picked up, but Amazon's profit forecast was a little light.
CEO Andy Jassy struck a defiant tone in the company's conference call to discuss results, swiping at competitors and boasting about AWS's many new offerings.
After a 3-month hiatus, I am resuming accumulation of Amazon in light of its Q4 2025 report and the subsequent stock dip. While Amazon missed EPS expectations slightly, Q4 revenue and Q1 outlook beat estimates. Despite a $200B 2026 CAPEX guide and negative near-term free cash flow projection, AMZN's dominance in cloud, ads, and retail supports long-term investments in AI.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.